2ndWorldCongresson InterventionalTherapiesforType2Diabetes › download... · HostedBy March 28-30,...

Hosted By

March 28-30, 2011Hi l ton New York • New York, NY • USA

2nd World Congress onInterventional Therapies for Type 2 Diabetes

Congress Program

Congress DirectorFrancesco Rubino, MD

www.wcidt.org

Welcome to the 2nd World Congress onInterventional therapies for Type 2 diabetes

1

Francesco Rubino, MDCongress Director

Dear Colleagues and Friends,

Several gastrointestinal (GI) operations originally designed to treat morbid obesity alsocause dramatic improvement or even remission of type 2 diabetes. The mechanismsby which surgery controls hyperglycemia remain elusive. Increasing evidence suggeststhat weight-independent mechanisms may play a role in the surgical control of diabetes.This knowledge challenges current paradigms of disease pathogenesis and points to thegastrointestinal tract as a potential target for the development of less invasive interventionaltherapies and novel pharmaceuticals.

Previously, the Diabetes Surgery Summit (Rome 2007) and the 1st World Congress onInterventional Therapies for Type 2 Diabetes (New York 2008), have raised attention aboutthe role of gastrointestinal surgery for the treatment of diabetes: opportunities andlimitations of this emerging field are now the matter of a growing debate.

The debate continues with the 2nd World Congress on Interventional Therapies for Type 2Diabetes. A multidisciplinary group of clinicians, scientists and policy makers will addressbarriers that still prevent access to surgical treatment of diabetes in eligible patients anddevelop an agenda of research priorities to improve patients selection and elucidatemechanisms of diabetes control.

A stellar Faculty of leading international scientists will also discuss how the lessons learnedfrom study of gastrointestinal interventions may improve understanding of diabetes andprovide a lead for future treatments of curative intent.

On behalf of the organizing committee and myself, I welcome you to this exciting,multidisciplinary event.

ENDORSING SOCIETIESThe 2nd World Congress on Interventional Therapies for Type 2 Diabetes is endorsed by the following organizations.

EDUCATIONAL PARTNER

American Association ofClinical Endocrinologists

™ 100 SW 75th Street Suite 201Gainesville, FL 32607

American Society for Metabolicand Bariatric Surgery

American GastroenterologicalAssociation

American Association ofEndocrine Surgeons

AsociacionDe Cirugia BariatricaY Metabolica De

GuatemalaAssociation for theStudy of Obesity

Asociation LatinoamericanaDe Circurjanos Endoscpistas

Asia Pacific, Metabolic &Bariatric Surgery Society

Belgian Endocrine Society

European Association forEndoscopic Surgery

Endocrine Society

Diabetes UK

IFSO Sweden

International AtherosclerosisSociety

Indian Association of GastrointestinalEndo-Surgeons

European Association forthe Study of Diabetes

International Federation for the Surgeryof Obesity and Metabolic Disorders

American Diabetes Association

2nd World Congress on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org

Canadian DiabetesAssociation

Emirates ObesitySurgery

Interest Group


2

European Associationfor Gastroenterology

and Endoscopy

This program is supported in name only by the American Heart Association’s Councils on Basic Cardiovascular Sciences,Clinical Cardiology, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, Kidney in CV Disease,

and High Blood Pressure Research. http://www.heart.org/HEARTORG/

Qatar DiabetesAssociation – Qatar Foundation

Obesity Surgery Society ofAustralia & New Zealand

Sociedad Argentinade Diabetes

Sociedad de Cirujanosde Chile

Sociedade Brasileirade Diabetes (SBD)

Sociedade Brasileira de CirurgiaBariatrica e Metabolica

Sociedad Espanolade Diabetes

Società Italiana di Chirurgia dell’Obesitàe delle malattie metaboliche

SocietàItaliana

di DiabetologiaSocietà Italiana dell'Obesità Società Italiana per la

Prevezione Cardiovascolare

The Society for Surgeryof the Alimentary Tract

Society of American Gastrointestinaland Endoscopic Surgeons

Swiss Society for the Study of MorbidObesity and Metabolic Disorders

The Philippine Society forMetabolic and Bariatric Surgery

Society forEndocrinology

Sociedade Brasileira deEndocronologia e Metabologia

Research Societyfor the Study ofDiabetes in India



National Obesity ForumJapan Society for the Studyof Obesity

Obesity & Metabolic SurgerySociety of India

The Obesity Society

3

The New YorkAcademy of Sciencs

Italian Society ofEndocrinology

2nd World Congress on Interventional Therapies for Type 2 Diabetes

The International Diabetes Federation (IDF)Position Statement on

Interventional Treatments of Type 2 DiabetesDuring the World Congress, the IDF will officially announce its Position Statement on

Metabolic/Bariatric Surgery and GI Interventions for the Treatment of Diabetes

Monday, March 28, 201111:10 am - 12:30 pm • Grand Ballroom, Hilton New York

Professor George AlbertiImperial College, London and Newcastle University, UK

Professor John B. DixonBaker IDI Heart & Diabetes Institute, Melbourne, Australia

Professor Pierre LefebvreIDF and University of Liege, Belgium

Dr. Carel Le RouxImperial College London, UK

Professor Jean-Claude MbanyaInternational Diabetes Federation, Cameroon

Professor Gertrude MingroneCatholic University of Rome, Italy

Professor Philip R. SchauerCleveland Clinic Lerner College of Medicine, USA

Professor Luc Van GaalAntwerp University Hospital, Belgium

Dr. David WhitingInternational Diabetes Federation, Belgium

Professor Bruce M. WolfeOregon Health and Science University (OHSU), USA

The consensus meeting was supported with an unrestricted educational grant by:Allergan Inc, Irvine, CA, USA

Ethicon, Ethicon Endo-Surgery, Inc, Cincinnati, Ohio, USAMetaCure Inc, Mount Laurel, NJ, USA

These companies played no role in the discussion or preparation of the IDF position statement.

The IDF consensus developing meeting was held at the IDF head office in Brussels, Belgium (5-6 December, 2010).This meeting was convened by:

Professor Stephanie AmielKing's College London, UK

Professor Louise A. BaurUniversity of Sydney, Australia

Professor Nam H. ChoAjou University School of Medicine, Korea

Dr. Bruno GelonezeUniversity of Campinas (UNICAMP), Brazil

Professor Jan Willem GreveAtrium Medical Center, Netherlands

Professor Linong JiPeking University People's Hospital, China

Dr. Muffazal LakdawalaSaifee Hospital, India

Professor Wei-Jei LeeMing-Sheng General Hospital, National TaiwanUniversity, Taiwan

Other attendees at the meeting were:

Professor Paul ZimmetBaker IDI Heart & Diabetes Institute, Melbourne, Australia

Professor Francesco RubinoWeill Cornell Medical College, New York, NY, USA

All panel members made a substantial contribution to the meeting and subsequent formulation of the position statement.

2nd World Congress on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org4

Contents

Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Endorsing Societies . . . . . . . . . . . . . . . . . . . . . . . . . . . .

International Diabetes Federation Statement. . . . . . . . . . . . . . .

General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Congress Advisory Committee . . . . . . . . . . . . . . . . . . . . . . .

Congress Program Committee . . . . . . . . . . . . . . . . . . . . .

Distinguished Faculty . . . . . . . . . . . . . . . . . . . . . . . . . .

Guest Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Program-At-A-Glance . . . . . . . . . . . . . . . . . . . . . . . . .

PROGRAM

Monday, March 28. . . . . . . . . . . . . . . . . . . . . . . . . .

Tuesday, March 29. . . . . . . . . . . . . . . . . . . . . . . . . .

Breakout Sessions/Workshops . . . . . . . . . . . . . . . . . . .

Wednesday, March 30. . . . . . . . . . . . . . . . . . . . . . . .

Faculty Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Exhibit Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diabetes: A Global Epidemic . . . . . . . . . . . . . . . . . . . . . . .

Gastrointestinal Procedures . . . . . . . . . . . . . . . . . . . . . .

Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Congress Sponsors . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


1

2-3

4

6-7

9

11-13

14-21

22

23-24

26-27

28-32

30-32

33-34

35

37-38

38

39

41

43-47

48-49

50

GENERAL INFORMATION


EDUCATIONAL DISCLAIMERThe primary purpose of this congress is education. Informationpresented, as well as publications, technologies, and/or servicesdiscussed, are intended to inform you about the knowledge,techniques, and experiences of the faculty who are willing toshare such information with colleagues. A diversity ofprofessional opinions exists on the topics of the Congress, andthe views of the conference’s faculty are solely for educationalpurposes. Faculty’s views neither represent those of the 2ndWorld Congress on Interventional Therapies for Type 2 Diabetesnor constitute endorsement by the endorsing societies listed inthis syllabus. The Congress declaims any and all liability ordamages to any individual attending this conference and forall claims, which may result from the use of information,publications, technologies, products and/or services of themeeting. Faculty disclosure statements have been providedby speakers and are included at the end of this syllabus.

ACCREDITATIONDue to the structure and multidisciplinary nature of the Congress,continuing medical education and nursing credits are notavailable through the Congress this year.

GUIDE TO MEETING ROOMS

Second Floor• Promenade - World Congress Registration• Clinton Suite - Press Office• Gibson Suite - Speaker Ready Room• Rhinelander Gallery - Exhibits, Poster Sessions,

Continental Breakfasts and Lunches• Sutton Center - Breakout Sessions• Sutton North/Beekman - Breakout Sessions• Sutton South/Regent - Breakout Sessions

Third Floor• Grand Ballroom - Opening Ceremony, Plenary Sessions• Trianon Ballroom - Welcome Reception

All meeting room floors being used for the World Congressare accessible by elevators. Escalators also provide accessbetween First, Second, and Third Floors.

The World Congress will take place March 28-30, 2011at the Hilton New York, 1335 Avenue of the Americas, New York, NY 10013

Telephone: (+1) 212-586-7000 • Guest Fax: (+1) 212-315-1374

SPEAKER READY ROOM

All Congress speakers are required to check in at the SpeakerReady Room no later than two hours in advance of yourpresentation. The Speaker Ready Room is located in theGibson Suite on the hotel’s second floor.

Speaker Ready Room Hours:

Sunday, March 27, 2011 2:00 pm - 6:00 pmMonday, March 28, 2011 7:00 am - 6:00 pmTuesday, March 29, 2011 6:30 am - 6:00 pmWednesday, March 30, 2011 7:00 am - 12:00 pm

REGISTRATION

Registration Hours:Sunday, March 27, 2011 10:30 am - 7:00 pmMonday, March 28, 2011 7:00 am - 9:00 pmTuesday, March 29, 2011 6:30 am - 7:00 pmWednesday, March 30, 2011 7:00 am - 2:00 pm

Only registered participants may attend the Scientific Sessionsand the Social Events offered by the World Congress.All registered participants are entitled to:

• Attend all Scientific Sessions• Attend the Exhibits, and the Poster Sessions• Receive Final Program and Abstracts• Breakfast and Coffee Breaks March 28-30 and BoxedLunches on March 28-29

BADGES

The official badge must be worn for admission to all activities ofthe Congress.

PRESS

Working press from print and electronic media may receivecomplimentary registration on submission of a copy of presscredentials and a completed registration form. A Press Officewill be available in the Clinton Suite on the 2nd floor.

Press Office Hours:

Monday, March 28, 2011 7:00 am - 6:00 pmTuesday, March 29, 2011 7:00 am - 6:00 pmWednesday, March 30, 2011 7:00 am - 12:00 pm


SCIENTIFIC EXHIBITS

Scientific Exhibits and Posters will be located inside theRhinelander Gallery on the hotel’s second floor. Exhibit andposter hours are:Monday, March 28 7:00 am - 6:45 pm(Poster Session from 5:45 – 6:45 pm)Tuesday, March 29 6:30 am – 3:00 pm

LANGUAGE

The official language of the Congress is English. No simultaneoustranslation is provided.

WIFI HOTSPOT

A wifi hotspot is offered to participants to remotely accessInternet. The wifi hotspot is located inside the RhinelanderBallroom. Funding for the 2nd World Congress wifi hotspot isgraciously provided by Allergan.

MEALS & COFFEE BREAKS

Continental breakfast and box lunch will be available inside theRhinelander Gallery on Monday and Tuesday. Coffee breaks, aswell as Wednesday’s continental breakfast, will be located inthe Grand Ballroom Foyer.

WELCOME RECEPTION

Please join us for this unique opportunity to network with faculty,guest experts and colleagues. Areas of conversation will benestled among tastes and flavors reminiscent of New YorkNeighborhoods. Relax and enjoy the music of the best coverband in New York City ~ Café Wha? ~ with your colleaguesand friends to your favorite funk, classic rock, rhythm and andmeringue dance music.

Trianon Ballroom, Hilton New YorkMonday, March 28, 20118:00 pm - 10:00 pm

Tickets to the Welcome Reception are available for purchase atthe Registration Desk until 12:00 pm on Monday, March 28. Aticket and official Congress badge are required for admittance.

CERTIFICATE OF ATTENDANCE

A Certificate of Attendance is available upon request, from theRegistration Desk at the end of the Congress. The request formmay be found in your registration bag.

BUSINESS CENTER

A fully staffed Business Center is located on the 2nd floor ofthe New York Hilton, adjacent to Guest Elevators (next to theMadison Suite). Services include computer stations, FaxServices, Copy Machine, and Package Delivery.

Business Center Hours:Monday - Friday 7:00 am - 7:00 pmSaturday & Sunday 9:00 am - 5:00 pm

The Business Center may also be accessed 24 hours a dayusing your New York Hilton guest room key. The BusinessCenter can be contacted though a house phone at Ext. 5212or by calling (+1) 212-399-1977.

LOST & FOUNDPlease return all lost or found items to the Registration Desk.All items left at the World Congress Lost and Found will beturned over to New York Hilton upon conclusion of the event.

IN CASE OF EMERGENCYIn the event of any emergency situation, dial extension 5747 or66 from any house phone or your hotel room. New York Hiltonhas security personnel trained in first aid and CPR and a directlink to NYC emergency services such as ambulance andparamedics to render aid quickly.

SMOKINGThe New York Hilton sleeping rooms, public and meeting spaceis 100% smoke-free. There is a “Smoking Oasis” out front ofthe Hotel on the main ramp.

PERSONAL INSURANCE COVERAGERegistration for the World Congress implies that the participantagrees that neither the Organizing Committee (consisting of theAdvisory and Program Committees), the Weill Cornell MedicalCollege, the NewYork-Presbyterian Hospital nor the GiovanniLorenzini Medical Foundation assume any liability or responsibilitywhatsoever. Congress delegates are requested to make theirown arrangements for medical, travel, and personal insurance.

CELLULAR PHONES, BEEPERS & ELECTRONIC DEVICESIn consideration of fellow participants, it is requested that all cellphones, beepers, pagers, and other electronic devices beturned off or set to the silent/vibrate mode during all ScientificSessions to avoid disruption.

AMERICANS WITH DISABILITIES STATEMENTThe World Congress wishes to take those steps to ensure thatno individual with a disability is excluded, denied services,segregated, or otherwise related to differently because of theabsence of auxiliary aids and services identified in the Americanswith Disabilities Act. If any such services are necessary in orderto participate in the Congress, please communicate your needsin advance.

The Congress can assist with special needs (e.g. physical,dietary). For assistance, please stop by the Registration Desk.

PROGRAM CHANGES AND MESSAGE BOARDA Program Change and Message Board is located in theRegistration Area on the 2nd Floor Promenade, where any lastminute changes to the Program will be posted.

CANCELLATION OF THE CONGRESSIn the unlikely event that the 2nd World Congress onInterventional Therapies for Type 2 Diabetes is abbreviated orcancelled for any reason whatsoever, the Weill Cornell MedicalCollege, the NewYork-Presbyterian Hospital and the GiovanniLorenzini Medical Foundation and Fondazione GiovanniLorenzini reserve the right, in their sole discretion, to unilaterallyterminate the Congress. In such case, the registrant and/or anyfunding/supporting organization hereby agrees to waive anyclaim against the Weill Cornell Medical College, the NewYork-Presbyterian Hospital and the Giovanni Lorenzini MedicalFoundation and Fondazione Giovanni Lorenzini, for damages orcompensation including but not limited to, fees for registration,housing, airfare, and incidental charges.

2nd World Congress on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org 7

Congress Advisory Committee


CONGRESS DIRECTOR

Francesco Rubino, MDChief, GI Metabolic SurgeryDirector, Diabetes Surgery CenterWeill Cornell Medical CollegeNewYork-Presbyterian HospitalNew York, NY USA

Linda Cann, MSEdManaging Director, Professional Education,Conventions and International AffairsAmerican Diabetes AssociationAlexandria, VA USA

Ricardo V. Cohen, MDCo-DirectorThe Center for the Surgical Treatment ofMorbid Obesity & Metabolic DisorderAlemão Oswaldo Cruz HospitalSão Paulo, Brazil

David E. Cummings, MDProfessor, MedicineMetabolism, Endocrinology & NutritionDeputy Director, Diabetes EndocrinologyResearch CenterUniversity of Washington School of MedicineSeattle, WA USA

Antonio M. Gotto, Jr., MD, DPhilThe Stephen and Suzanne Weiss DeanProfessor, MedicineProvost, Medical AffairsWeill Cornell Medical CollegeNew York, NY USA

Lee M. Kaplan, MD, PhDProfessor, MedicineHarvard Medical SchoolDirector, MGH Weight CenterMassachusetts General HospitalBoston, MA USA

M. Sue Kirkman, MDSenior Vice President, Medical Affairsand Community InformationAmerican Diabetes AssociationAlexandria, VA USA

Harold E. Lebovitz, MDProfessor, MedicineSUNY Health Science Center at BrooklynBrooklyn, NY USA

Fabrizio Michelassi, MDLewis Atterbury Stinson Professor andChairmanDepartment of SurgeryWeill Cornell Medical CollegeSurgeon-in-ChiefNewYork-Presbyterian Hospital/WeillCornell Medical CenterNew York, NY USA

Alfons Pomp, MD, FRCSC, FACSLeon C. Hirsch Professor of SurgeryChief, Section Laparoscopic & BariatricSurgeryWeill Cornell Medical CollegeNew York, NY USA

Philip Schauer, MDProfessor, SurgeryLerner College of MedicineDirector, Advanced Laparoscopic &Bariatric SurgeryCleveland ClinicCleveland, OH USA

Paul Zimmet, MD, PhDDirector EmeritusDirector International ResearchBaker IDI Heart and Diabetes InstituteMelbourne, Australia


Program Committee



CHAIRHarold E. Lebovitz, MDProfessor, MedicineSUNY Health Science Center at BrooklynBrooklyn, NY USA

CHAIRDavid E. Cummings, MDProfessor, MedicineMetabolism, Endocrinology & NutritionDeputy Director, Diabetes EndocrinologyResearch CenterUniversity of Washington School of MedicineSeattle, WA USA

CHAIRPaul Zimmet, MD, PhDDirector EmeritusDirector International ResearchBaker IDI Heart and Diabetes InstituteMelbourne, Australia

CO-CHAIRPhillip Schauer, MDProfessor, SurgeryLerner College of MedicineDirector, Advanced Laparoscopic &Bariatric SurgeryCleveland ClinicCleveland, OH USA

CO-CHAIRLee Kaplan, MD, PhDProfessor, MedicineHarvard Medical SchoolDirector, MGH Weight CenterMassachusetts General HospitalBoston, MA USA

CO-CHAIRDavid R. Flum, MD, MPHProfessor, SurgeryAssociate Chair, ResearchUniversity of WashingtonSeattle, WA USA

CONGRESS DIRECTOR

CLINICAL TRACK

RESEARCH TRACK

POLICY TRACK


Program Committee


Domenico Accili, MDProfessor, MedicineDirector, Diabetes and EndocrinologyResearch CenterColumbia UniversityNew York, NY USA

Louis J. Aronne, MD, FACPClinical Professor, MedicineDirector, Comprehensive Weight ControlProgramWeill Cornell Medical CollegeNew York, NY USA

Ricardo V. Cohen, MDCo-DirectorThe Center for the Surgical Treatment ofMorbid Obesity & Metabolic DisorderAlemão Oswaldo Cruz HospitalSão Paulo, Brazil

John B. Dixon, MBBS, PhD,FRACGP, FRCPEdinNHMRC Senior Research Fellow, Vascularand Hypertension-Obesity ResearchBaker IDI Heart and Diabetes InstituteMelbourne, Australia

Robin S. Goland, MDProfessor of Clinical Medicine andPediatricsColumbia University College ofPhysicians & SurgeonsNew York, NY USA

Allison B. Goldfine, MDAssociate Professor, MedicineHarvard Medical SchoolSection Head, Clinical ResearchJoslin Diabetes CenterBoston, MA USA


Samuel Klein, MDWilliam H. Danforth Professor of Medicineand Nutritional ScienceWashington University School of MedicineSt. Louis, MO USA

Rudolph L. Leibel, MDChristopher J. Murphy Memorial Professorof Diabetes ResearchCo-Director, Naomi Berrie DiabetesCenter;Head, Division of Molecular GeneticsColumbia University Medical CenterNew York, NY USA

Carel W. Le Roux, MB, ChBReader, Investigative ScienceDepartment of MedicineImperial CollegeLondon, UK


Program Committee


Timothy E. McGraw, PhDProfessor, BiochemistryWeill Cornell Medical CollegeNew York, NY USA

Jeffrey I. Mechanick, MDClinical Professor, MedicineEndocrinology, Diabetes and Bone DiseaseDirector, Metabolic SupportMount Sinai School of MedicineNew York, NY USA

Jesse Roth, MD, FACPProfessor, MedicineAlbert Einstein College of MedicineInvestigator,Feinstein Institute for Medical ResearchManhasset, NY USA

Bruce Wolfe, MDProfessor, SurgeryOregon Health & Science UniversityPortland, OR USA


Distinguished Faculty


Domenico Accili, MDProfessor, MedicineDirector, Diabetes & EndocrinologyResearch CenterColumbia UniversityNew York, NY USA

Ted D. Adams, PhD, MPHProgram Director,Cardiovascular Genetics,University of Utah and Health FitnessInstituteLDS Hospital, Intermountain HealthcareSalt Lake City, UT USA

Sir K. George Alberti, MA, DPhil,BM BChSenior Research Investigator, MedicineImperial CollegeLondon, UK

Stephanie A. Amiel, MDRD Lawrence Professor, Diabetic MedicineKing’s CollegeLondon, UK

Caroline M. Apovian, MDProfessor, MedicineBoston University School of MedicineDirector, Nutrition and WeightManagementBoston Medical CenterBoston, MA USA

Louis J. Aronne, MD, FACPClinical Professor, MedicineDirector, Comprehensive Weight ControlProgramWeill Cornell Medical CollegeNew York, NY USA

Nicola Basso, MD, FACSProfessor, SurgeryParide Stefanini Department of SurgerySapienza University of RomeAzienda Policlinico Umberto IRome, Italy

Richard N. Bergman, PhDKeck Professor of MedicineChair, Department of Physiology andBiophysicsKeck School of MedicineUniversity of Southern CaliforniaLos Angeles, CA USA

Zachary T. Bloomgarden, MDClinical Professor, Medicine,Endocrinology, Diabetes, & Bone DiseaseMount Sinai School of MedicineNew York, NY USA

Stacy A. Brethauer, MDAssociate Staff SurgeonLaparoscopic & Bariatric SurgeryCleveland ClinicCleveland, OH USA




Michael S. Brown, MDW.A. (Monty) Moncrief Distinguished Chair,Cholesterol & Arteriosclerosis ResearchRegental Professor, Molecular GeneticsThe University of Texas SouthwesternMedical CenterDallas, TX USA1985 Nobel Laureate for Medicine orPhysiology

Henry Buchwald, MD, PhDProfessor, Surgery and BiomedicalEngineeringUniversity of MinnesotaMinneapolis, MN USA

Pradeep Chowbey, MD, FACSChair, Minimal Access SurgeryJoint Managing Director, Max Instituteof Minimal Access, Metabolic & BariatricSurgeryNew Delhi, India

Ricardo V. Cohen, MDCo-DirectorThe Center for the Surgical Treatment ofMorbid Obesity and Metabolic DisorderAlemão Oswaldo Cruz HospitalSão Paulo, Brazil

David E. Cummings, MDProfessor, MedicineMetabolism, Endocrinology & NutritionDeputy Director, Diabetes EndocrinologyResearch CenterUniversity of Washington School of MedicineSeattle, WA USA

Tamara Darsow, PhDVice President Research ProgramsAmerican Diabetes AssociationAlexandria, VA USA

Professor the Lord Ara Darzi ofDenham, PC KBE HonFREngFmedSciProfessor, SurgeryImperial College LondonLondon, UK

Aureo Ludovico De Paula, MDDirector, SurgerySpecialty HospitalGoias, Brazil

Ralph DeFronzo, MDProfessor, MedicineChief, Diabetes DivisionUniversity of Texas Health ScienceCenterSan Antonio, TX USA


Stefano Del Prato, MDProfessor, Endocrinology andMetabolismChief, Section of DiabetesUniversity of PisaCisanello HospitalPisa, Italy



John B. Dixon, MBBS, PhD,FRACGP, FRCPEdinNHMRC Senior Research Fellow,Vascular and Hypertension-ObesityResearchBaker IDI Heart and Diabetes InstituteMelbourne, Australia

Robert H. Eckel, MDProfessor, MedicineProfessor, Physiology and BiophysicsUniversity of Colorado - AnshutzMedical CampusAurora, CO USA

Ele Ferrannini, MDProfessor, Internal MedicineUniversity of PisaPisa, Italy

David R. Flum, MD, MPHProfessor, SurgeryAssociate Chair, ResearchUniversity of WashingtonSeattle, WA USA

John Funder, MD, PhD, FRACP,FRCPProfessor, MedicinePrince Henry's InstituteClayton, Australia

Michel Gagner, MDClinical Professor, SurgeryClinique Michel Gagner MD, Inc.Montreal, QC Canada

Manoel Galvao Neto, MDSurgeon & GastroenterologistScientific CoordinatorGastro Obeso CenterSão Paulo, Brazil

Allison B. Goldfine, MDAssociate Professor, MedicineHarvard Medical SchoolSection Head, Clinical ResearchJoslin Diabetes CenterBoston, MA USA

Joseph L. Goldstein, MDJulie and Louis A. Beecherl Distin-guished Chair in Biomedical ScienceRegental Professor, Molecular GeneticsThe University of Texas SouthwesternMedical CenterDallas, TX USA1985 Nobel Laureate for Medicine orPhysiology


Antonio M. Gotto, Jr. , MD, DPhilThe Stephen and Suzanne Weiss DeanProfessor, MedicineProvost, Medical AffairsWeill Cornell Medical CollegeNew York, NY USA



Jan Willem M. Greve, MD, PhDProfessor, SurgeryChair, Department of SurgeryAtrium Medical Center ParkstadHeerleen, Limburg The Netherlands

Peter Hill, MD, PhDCorporate Medical DirectorMedical Administration DepartmentHamad Medical CorporationDoha, Qatar

Bjorn Hofmann, MSc, PhDProfessor, Medical EthicsInstitute for Health and SocietyUniversity of OsloOslo, Norway

Jens Juul Holst, MDProfessor, Medical PhysiologyInstitute of Biomedical SciencesCopenhagen, Denmark

Linong Ji, MDCo-Director, Peking University DiabetesCenterDirector, Department Of EndocrinologyAnd Metabolism, Peking UniversityPeople’s HospitalPresident, Chinese Diabetes SocietyVice President,Chinese Endocrinologist AssociationBeijing, China

Shashank R. Joshi, MBBS, MD,DMProfessor, ConsultantGrant Medical College and Sir JJ Groupof HospitalsMumbai, India

Steven H. Kahn, MB, ChBProfessor, MedicineVA Puget Sound Health Care SystemUniversity of WashingtonSeattle, WA USA

Lee Kaplan, MD, PhDProfessor, MedicineHarvard Medical SchoolDirector, MGH Weight CenterMassachusetts General HospitalBoston, MA USA

Catherine Keating, MPHSenior Research FellowDeakin Health Economics, Faculty ofHealthDeakin UniversityMelbourne, Australia





Samuel Klein, MDWilliam H. Danforth Professor ofMedicine and Nutritional ScienceWashington University School ofMedicineSt Louis, MO USA

Judith Korner, MD, PhDAssociate Professor, MedicineDirector, Weight Control CenterColumbia University Medical CenterNew York, NY USA

Blandine B. Laferrere, MDAssociate Professor, MedicineColumbia University College of Physiciansand SurgeonsNew York, NY USA

David Lautz, MDDirector of Bariatric SurgeryHarvard Medical School, Brigham andWomen's HospitalBoston, MA USA

Carel W. Le Roux, MD, PhDReader, Investigative ScienceDepartment of MedicineImperial CollegeLondon, UK

Harold E. Lebovitz, MDProfessor, MedicineSUNY Health Science Center at BrooklynBrooklyn, NY USA

Frank Lefevre, MDAssociate Professor, MedicineSenior Scientist, BCBSA TechnologyEvaluation CenterNorthwestern Feinberg School ofMedicineChicago, IL USA

Rudolph L. Leibel, MDChristopher J. Murphy Memorial Professorof Diabetes ResearchCo-Director, Naomi Berrie Diabetes CenterHead, Division of Molecular GeneticsColumbia University Medical CenterNew York, NY USA

Muffazal Abdulkader Lakdawala, MDChief, Minimal Access & Bariatric SurgeryDepartmentCentre for Obesity and Diabetes SupportSaifee HospitalMumbai, India


Ruth E. Ley, PhDAssistant Professor, MicrobiologyCornell UniversityIthaca, NY USA



Timothy E. McGraw, PhDProfessor, BiochemistryWeill Cornell Medical CollegeNew York, NY USA

Jeffrey I. Mechanick, MDClinical Professor, Medicine,Endocrinology, Diabetes and BoneDiseaseDirector, Metabolic SupportMount Sinai School of MedicineNew York, NY USA

Geltrude Mingrone, MD, PhDProfessor, Internal Medicine,EndocrinologyCatholic University of the Sacred HeartRome, Italy

Xavier Pi-Sunyer, MDChief of Endocrinology andProfessor of MedicineSt. Luke’s Roosevelt HospitalColumbia UniversityNew York, NY USA

Alfons Pomp, MD, FRCSC,FACSLeon C. Hirsch Professor of SurgeryChief, Section Laparoscopic &Bariatric SurgeryWeill Cornell Medical CollegeNew York, NY USA

Walter J. Pories, MD, FACSProfessor, Surgery, Biochemistryand Exercise and Sports ScienceEast Carolina UniversityGreenville, NC USA

Jesse Roth, MD, FACPProfessor, MedicineAlbert Einstein College of MedicineInvestigator, Feinstein Institute forMedical ResearchManhasset, NY USA

Rui Li, PhDHealth EconomistCenters for Disease Control andPreventionAtlanta, GA USA


John J. Moore, DO, FAAFPPatient Management Medical Directorfor the Northeast RegionAETNABlue Bell, PA USA

19




Gary Schwartz, PhDProfessor of Medicine & NeuroscienceAlbert Einstein College of Medicine ofYeshiva UniversityBronx, NY USA

Randy J. Seeley, PhDDirector, Cincinnati Diabetes Obesity CenterUniversity of CincinnatiDonald C. Harrison Endowed Professorin MedicineMetabolic Diseases InstituteCincinnati, OH USA

Gerald I. Shulman, MD, PhDInvestigator, Howard Hughes Medical InstituteProfessor, Physiological Chemistry,Medicine (Endocrinology) and Cellular &Molecular PhysiologyAssociate Director, Diabetes-EndocrinologyResearch CenterAssociate Director, Medical Scientist TrainingProgramYale University School of MedicineNew Haven, CT USA

Lars V. Sjöström, MD, PhDProfessor Emeritus, SOS SecretariateInternal MedicineSahlgrenska University HospitalGöteborg, Sweden

Myrlene Staten, MDSenior Advisor, Diabetes TranslationalResearchNIDDK, National Institutes of HealthBethesda, MD USA

Harvey J. Sugerman, MDEmeritus Professor, SurgeryEditor-in-Chief, Surgery for Obesity andRelated DiseasesVirginia Commonwealth UniversityRichmond, VA USA

Sean D. Sullivan, PhDProfessor, Health Sciences andDepartment of PharmacyAssociate Dean for ResearchUniversity of Washington Schoolof PharmacySeattle, WA USA

Mohammed Fathy Saoud, PhDPresidentQatar FoundationDoha, Qatar

Phillip Schauer, MDProfessor, SurgeryLerner College of MedicineDirector, Advanced Laparoscopic &Bariatric SurgeryCleveland ClinicCleveland, OH USA


Tess Van Der Merwe, MBChB, PhDDirectorCentres of Excellence for MetabolicMedicine and SurgeryGauteng, South Africa



James Young, MDProfessor, MedicineExecutive DeanLerner College of MedicineInstitute ChairEndocrinology & Metabolism InstituteCleveland ClinicCleveland, OH USA

Paul Zimmet, MD, PhDDirector EmeritusDirector International ResearchBaker IDI Heart and Diabetes InstituteMelbourne, Australia

Mahmoud Ali Zirie, MDProfessor, MedicineHead, Endocrinology Diabetes DivisionHamad Medical CorporationDoha, Qatar

Bruce Wolfe, MD, FACSProfessor, SurgeryOregon Health & Science UniversityPortland, OR USA

Carol H. Wysham, MDClinical Associate Professor, MedicineUniversity of Washington School ofMedicineSection Head, Rockwood Center forDiabetes & EndocrinologyRockwood ClinicSpokane, WA USA


In addition to contributing to the scholarship of the audience, the presence of Guest Experts is meant to facilitate a livelydiscussion and debate throughout the course of the World Congress. Guest Experts will also steer group discussion duringbreakout sessions on Tuesday, March 29th. We would like to thank the following individuals for providing a uniqueperspective to the emerging field of interventional diabetology:

Guest Experts


Vince Aguirre, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Luiz Vicente Berti, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Morris J. Birnbaum, MD, PhD . . . . . . . . . . . . . . . . . . . . . . .

Robin Blackstone, MD, FACS . . . . . . . . . . . . . . . . . . . . . . .

Camilo Boza, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . .

David J. Brillon, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marco Castagneto, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Lee-Ming Chuang, MD, PhD . . . . . . . . . . . . . . . . . . . . . . .

Gregory F. Dakin, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Alex Escalona, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Mathias A. Fobi, MD, FACS, FASMBS, FICS, FACN . . . . . . .

Paolo Gentileschi, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Giovanni Ghirlanda, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Ramen Goel, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Neil E. Hutcher, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . .

William B. Inabnet, III, MD, FACS . . . . . . . . . . . . . . . . . . . . .

Kazunori Kasama, MD, FACS . . . . . . . . . . . . . . . . . . . . . .

Subhash Kini, MD, FRCS, FACS . . . . . . . . . . . . . . . . . . . . .

John G. Kral, MD, PhD, FACS . . . . . . . . . . . . . . . . . . . . . . .

Wei-Jei Lee, MD, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . .

Bassem M. Masri, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Francois Pattou, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Antonio E. Pontiroli, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Almino Ramos, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Mitch Roslin, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . . .

Naina Sinha, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

April D. Strader, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Richard Stubbs, MD, FRCS, FRACS . . . . . . . . . . . .

Michel Suter, MD . . . . . . . . . . . . . . . . . . . . . . . . . . .

Julio Teixeira, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . . .

Antonio José Torres, MD, PhD . . . . . . . . . . . . . . . . . . . . . .

Jonathan A. Waitman, MD . . . . . . . . . . . . . . . . . . . . . . . . .

USA

Brazil

USA

USA

Chile

USA

Italy

Taiwan

USA

Chile

USA

Italy

Italy

India

USA

USA

Japan

USA

USA

Taiwan

USA

France

Italy

Brazil

USA

USA

USA

New Zealand

Switzerland

USA

Spain

USA


CLINICAL TRACK SESSION I (Grand Ballroom)

Program At-A-Glance

Clinical Outcomes of Conventional and Surgical Treatments for T2DM

The International Diabetes Federation (IDF) Position Statement on InterventionalTreatments of Type 2 Diabetes

CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy

Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management

TUESDAY, MARCH 29, 2011

Mechanisms of Action of Surgery

Novel Experimental Approaches for Diabetes/Obesity

8:35 am - 10:50 am

POLICY TRACK SESSION I (Grand Ballroom)11:10 am - 12:30 pm

CLINICAL TRACK SESSION II (Grand Ballroom)1:30 pm - 3:00 pm

CLINICAL TRACK SESSION III (Grand Ballroom)3:20 pm - 5:45 pm

RESEARCH TRACK SESSION I (Grand Ballroom)7:30 am - 9:40 am

RESEARCH TRACK SESSION II (Grand Ballroom)9:40 am - 11:10 am


MONDAY, MARCH 28, 20117:00 am - 8:00 am

7:00 am - 9:00 pm

7:00 am - 6:45 pm

8:00 am - 8:20 am

8:20 am - 8:35 am

10:50 am - 11:10 am Refreshment Break (Grand Ballroom Foyer)

Lunch (Rhinelander Gallery)

Refreshment Break (Grand Ballroom Foyer)

Poster Session (Rhinelander Gallery)

Welcome Reception (Trianon Ballroom)

Continental Breakfast (Rhinelander Gallery)

Registration Open (2nd Floor Promenade)

Exhibits and Posters (Rhinelander Gallery)

Opening Ceremony (Grand Ballroom)

Introduction of the World Congress: Scope and MethodsF. Rubino (New York, NY USA)

12:30 pm - 1:30 pm

3:00 pm - 3:20 pm

5:45 pm - 6:45 pm

8:00 pm - 11:00 pm

Continental Breakfast (Rhinelander Gallery)


Exhibits and Posters (Rhinelander Gallery)

6:30 am - 7:30 am

6:30 am - 7:00 pm

6:30 am - 3:00 pm


Refreshment Break (Grand Ballroom Foyer)11:10 am - 11:30 am

Global Burden of Diabetes and Resource Availability for Interventional Approaches

Cost Effectiveness of Diabetes Surgery: Implications for Public and Private HealthInsurance

Breakout SessionsClinical (Sutton North/Beekman)Research (Sutton Center)Policy (Sutton South/Regent)

WEDNESDAY, MARCH 30, 2011

The Role of the Gut in the Physiology and Pathophysiology of Obesity and Diabetes

Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone AxisM.S. Brown (Dallas, TX USA)J.L. Goldstein (Dallas, TX USA)

The GI tract: Could it be the missing link between obesity and diabetes?

Presentation of Executive Summaries and Conclusions

POLICY TRACK SESSION II (Grand Ballroom)

2:00 pm - 3:00 pm

POLICY TRACK SESSION III (Grand Ballroom)3:00 pm - 4:30 pm

BREAKOUT SESSIONS AND WORKSHOPS (Sutton Complex Rooms)4:50 pm - 6:50 pm

KEYNOTE LECTURE (Grand Ballroom)

8:00 am - 9:00 am

RESEARCH TRACK SESSION IV (Grand Ballroom)9:00 am - 10:40 am

PANEL DISCUSSION (Grand Ballroom)11:00 am - 12:00 pm

EXECUTIVE SUMMARIES/TAKE HOME MESSAGE (Grand Ballroom)12:00 pm - 1:15 pm

World Congress Adjourns

Defining Priorities for Clinical Research in Metabolic/Diabetes SurgeryRESEARCH TRACK SESSION III (Grand Ballroom)11:30 am - 1:00 pm


Lunch (Rhinelander Gallery)1:00 pm - 2:00 pm

4:30 pm - 4:50 pm


Continental Breakfast (Grand Ballroom Lobby)


7:00 am - 2:00 pm

7:00 am - 8:00 am

10:40 am - 11:00 am

1:20 pm



TUESDAY, MARCH 29, 2011 (cont’d)

24

8:00 am - 8:20 amGrand Ballroom

8:20 am - 8:35 amGrand Ballroom

POLICY TRACK SESSION I 11:10 am - 12:30 pm Grand Ballroom

Opening Ceremony

Introduction of the World Congress: Scope and MethodsF. Rubino (New York, NY USA)

CLINICAL TRACK SESSION I 8:35 am - 10:50 am Grand Ballroom

Clinical Outcomes of Conventional and Surgical Treatments for T2DMChairs: W. Pories (Greenville, NC USA) • H.E. Lebovitz (Brooklyn, NY USA)

Glycemic and metabolic control with current pharmacologic treatmentsS. Del Prato (Pisa, Italy)

Glycemic and metabolic outcomes with bariatric/metabolic surgery: overviewP. Schauer (Cleveland, OH USA)

Long-term prevention and remission of diabetes after bariatric surgery in the SOS studyL. Sjöström (Göteborg, Sweden)

Safety profiles of pharmaceutical approachesH.E. Lebovitz (Brooklyn, NY USA)

Safety profiles of surgical approaches: short and long termB.M. Wolfe (Portland, OR USA)

Panel DiscussionPanelists: S.A. Amiel (London, UK), Z.T. Bloomgarden (New York, NY USA), J. Dixon (Melbourne,Australia), A. Pomp (New York, NY USA), H. Buchwald (Minneapolis, MN USA), A.B. Goldfine (Boston, MAUSA), K.G. Alberti (London, UK), J.I. Mechanick (New York, NY USA), X. Pi-Sunyer (New York, NY USA)

COFFEE BREAK (Grand Ballroom Foyer)

8:35 am - 8:55 am

8:55 am - 9:15 am

9:15 am - 9:30 am

9:30 am - 9:45 am

9:45 am - 10:00 am

10:00 am - 10:50 am

10:50 am - 11:10 am

The International Diabetes Federation (IDF) Position Statement on Interventional Treatments of Type 2DiabetesChairs: J. Dixon (Melbourne, Australia) • K.G. Alberti (London, UK)

Existing guidelines for surgical treatment of obesity and diabetes (NIH, DSS, ADA)L.M. Kaplan (Boston, MA USA)

The IDF position statement on interventional therapies for type 2 diabetesP. Zimmet (Melbourne, Australia)

Panel DiscussionPanelists: C. Wysham (ADA) (Seattle, WA USA), J.I. Mechanick (AACE) (New York, NY USA), S.A. Amiel(Diabetes UK) (London, UK), X. Pi-Sunyer (NHLBI) (New York, NY USA), A.M. Gotto (New York, NY USA),F. Rubino (New York, NY USA), R.H. Eckel (Aurora, CO USA)

LUNCH BREAK (Rhinelander Gallery)

11:10 am - 11:20 am

11:20 am - 11:40 am

11:40 am - 12.30 pm

12:30 pm - 1:30 pm

MONDAY, MARCH 28, 2011


CONTINENTAL BREAKFAST (Rhinelander Gallery)7:00 am - 8:00 am


Scientific Program

CV risk, CVD and diabetes-related mortality: impact of pharmacologic approachesR.H. Eckel (Aurora, CO USA)

Long-term (20 years) impact of bariatric surgery on CV risk and CVD: an update from theSOS studyL. Sjöström (Göteborg, Sweden)

The impact of bariatric/metabolic surgery on CV risk and long-term survivalT.D. Adams (Salt Lake City, UT USA)

Panel DiscussionPanelists: R. DeFronzo (San Antonio, TX USA), E. Ferrannini (Pisa, Italy), S.R. Joshi (Mumbai, India), S.E.Kahn (Seattle, WA USA), J. Young (Cleveland, OH USA), H.J. Sugerman (Richmond, VA USA), W. Pories(Greenville, NC USA)


CLINICAL TRACK SESSION II 1:30 pm - 3:00 pm Grand Ballroom

1:30 pm - 1:50 pm

1:50 pm - 2:05 pm

2:05 pm - 2:15 pm

2:15 pm - 3:00 pm

3:00 pm - 3:20 pm

CLINICAL TRACK SESSION III 3:20 pm - 5:45 pm Grand Ballroom

3:20 pm - 3:35 pm

3:35 pm - 3:50 pm

3:50 pm - 4:05 pm

4:05 pm - 4:40 pm

4:40 pm - 4:55 pm

4:55 pm - 5:15 pm

5:15 pm - 5:45 pm

5:45 pm - 6:45 pm

8:00 pm

Predicting factors of diabetes control/reasonable criteria for surgical indicationJ. Korner (New York, NY USA)

Preoperative management of diabetic patientsC.M. Apovian (Boston, MA USA)

Which surgical procedure is best? Summary of available evidence from comparativeclinical studies in high and low BMI patientsH.J. Sugerman (Richmond, VA USA)

Panel DiscussionPanelists: H.E. Lebovitz (Brooklyn, NY USA), S.R. Joshi (Mumbai, India), J.I. Mechanick (New York, NYUSA), J. Dixon (Melbourne, Australia), M. Gagner (Montreal, QC, Canada), R.V. Cohen (São Paulo, Brazil)

Postoperative management of obese and diabetic patients; the role ofintegrated/multimodality therapiesL. Aronne (New York, NY USA)

A rational and physiologic approach to the management of diabetes after surgeryR. DeFronzo (San Antonio, TX USA)

Panel DiscussionPanelists: C. Wysham (Seattle, WA USA), S.E. Kahn (Seattle, WA USA), R.N. Bergman (Los Angeles, CAUSA), L. Ji (Beijing, China), S. Del Prato (Pisa, Italy)

POSTER SESSION (Rhinelander Gallery)

WELCOME RECEPTION (Trianon Ballroom)

CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical TherapyChairs: A.M. Gotto (New York, NY USA) • K.G. Alberti (London, UK)

Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative ManagementChairs: L. Aronne (New York, NY USA) • J. Young (Cleveland, OH USA)



Scientific Program

Mechanisms of Weight Loss: beyond restriction and malabsorptionR.J. Seeley (Cincinnati, OH USA)

Effect of GI surgery on insulin secretion/sensitivityS. Klein (St. Louis, MO USA)

Effects of GI surgery on food choices and energy expenditureC.W. Le Roux (London, UK)

Effects of GI surgery on glucose homeostasisJ.J. Holst (Copenhagen, Denmark)

Debate: Diabetes control by GI surgery is explained by weight-independent mechanismsYes: D.E. Cummings (Seattle, WA USA)No: E. Ferrannini (Pisa, Italy)

Panel Discussion: Weight independent mechanisms of diabetes control: weighing theevidencePanelists: J. Korner (New York, NY USA), G. Mingrone (Rome, Italy), R.N. Bergman (Los Angeles, CA USA),R. DeFronzo (San Antonio, TX USA), B.B. Laferrere (New York, NY USA), G.J. Schwartz (New York, NY USA)

RESEARCH TRACK SESSION I 7:30 am - 9:40 am Grand Ballroom

7:30 am - 7:45 am

7:45 am - 8:00 am

8:00 am - 8:15 am

8:15 am - 8:30 am

8:30 am - 9:00 am8:30 am - 8:45 am8:45 am - 9:00 am

9:00 am - 9:40 am

TUESDAY, MARCH 29, 2011

Novel GI surgical procedures (DJB and Ileal Interposition: alone and with associated sleevegastrectomy)R.V. Cohen (São Paulo, Brazil)

Endoluminal procedures for obesity/diabetesS.A. Brethauer (Cleveland, OH USA)

Endoluminal devices for obesity/diabetesL.M. Kaplan (Boston, MA USA)

Pacing/GI electric stimulation for diabetesH.E. Lebovitz (Brooklyn, NY USA)

Panel DiscussionPanelists: J.W.M. Greve (Heerleen, Netherlands), M. Galvao Neto (São Paulo, Brazil), A. De Paula (Goiania,Brazil), W. Pories (Greenville, NC USA), J. Funder (Clayton, Australia), S.R. Joshi (Mumbai, India)

COFFEE BREAK (Grand Ballroom Lobby)

RESEARCH TRACK SESSION II 9:40 am - 11:10 am Grand Ballroom

9:40 am - 9:55 am

9:55 am - 10:10 am

10:10 am - 10:25 am

10:25 am - 10:40 am

10:40 am - 11:10 am

11:10 am - 11:30 am

Mechanisms of Action of Surgery

Chairs: L.M. Kaplan (Boston, MA USA) • S.E. Kahn (Seattle, WA USA)

Novel Experimental Approaches for Diabetes/ObesityChairs: H. Buchwald (Minneapolis, MN USA) • S. Klein (St. Louis, MO USA)


CONTINENTAL BREAKFAST (Rhinelander Gallery)6:30 am - 7:30 am


Scientific Program

POLICY TRACK SESSION II 2:00 pm - 3:00 pm Grand Ballroom

3:00 pm - 3:15 pm

3:15 pm - 3:30 pm

3:30 pm - 3:45 pm

3:45 pm - 4:30 pm

Review of what we know about cost-effectiveness of bariatric surgery with special regardto patients with diabetesC. Keating (Burwood, Australia)

How governments consider evidence on cost-effectivenessS.D. Sullivan (Seattle, WA USA)

How payers consider the evidence of cost and effectivenessF. Lefevre (Chicago, IL USA)

Panel Discussion: Simply cost-effective? Reconciling cost-evaluations related to diabetesinterventionsPanelists: R. Li (Atlanta, GA USA), C. Keating (Burwood, Australia), S.D. Sullivan (Seattle, WA USA),F. Lefevre (Chicago, IL USA), J.J. Moore (Blue Bell, PA USA)

Global Burden of Diabetes and Resource Availability for Interventional ApproachesChairs: P. Zimmet (Melbourne, Australia) • P. Chowbey (New Delhi, India)

POLICY TRACK SESSION III 3:00 pm - 4:30 pm Grand Ballroom

Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health InsuranceChairs: A. Darzi (London, UK) • D. Flum (Seattle, WA USA)

2:00 pm - 2:15 pm

2:15 pm - 2:30 pm

2:30 pm - 3:00 pm

The global epidemiology of diabetesP. Zimmet (Melbourne, Australia)

The global costs of diabetesR. Li (Atlanta, GA USA)

Panel Discussion: Specific regional challenges for diabetes prevention and treatmentPanelists: L. Ji (Beijing, China), J. Funder (Clayton, Australia), T. Van Der Merwe (Pretoria, South Africa),A. Darzi (London, UK), M. Ali Zirie (Doha, Qatar), R. Li (Atlanta, GA USA)

4:30 pm - 4:50 pm COFFEE BREAK (Grand Ballroom Foyer)



RESEARCH TRACK SESSION III 11:30 am - 1:00 pm Grand Ballroom

11:30 am - 11:45 am

11:45 am - 12:00 pm

12:00 pm - 12:15 pm

12:15 pm - 1:00 pm

1:00 pm - 2:00 pm

Clinical trials in diabetes surgery: overview of ongoing trials; challenges for study design,practical issues in surgical trialsA.B. Goldfine (Boston, MA USA)

Clinical trials in diabetes surgery: ethical aspectsB.M. Hofmann (Oslo, Norway)

Advantages and disadvantages of each design, multisite vs consortium model for largeclinical trialsF. Rubino (New York, NY USA)

Panel Discussion: Priorities for clinical research in diabetes surgery; costs/funding, ethicalaspectsPanelists: P. Schauer (Cleveland, OH USA), R. DeFronzo (San Antonio, TX USA), J. Korner (New York,NY USA), D. Lautz (Boston, MA USA), M. Staten (Bethesda, MD USA), F. Saoud (Doha, Qatar), T. Darsow(Alexandria, VA USA)

LUNCH BREAK (Rhinelander Gallery)

Defining Priorities for Clinical Research in Metabolic/Diabetes SurgeryChairs: A.B. Goldfine (Boston, MA USA) • J. Roth (Manhasset, NY USA)

29

Scientific Program

BREAKOUT SESSIONS AND WORKSHOPS4:50 pm - 6:50 pm

TUESDAY, MARCH 29, 2011 (continued)

Breakout Sessions for Interactive Discussion and Preparation of Executive Summary

Workshop A: Defining appropriate surgical candidates for diabetes surgery

Who should be referred for surgical treatment of diabetes?H.E. Lebovitz (Brooklyn, NY USA)

Expert Panel CommentsW.J. Pories (Greenville, NC USA), L.J. Aronne (New York, NY USA), R. DeFronzo (San Antonio, TX USA),J. Young (Cleveland, OH USA)

Q&A: Guest Experts and AudienceInteractive Opinion Polls

Workshop B: Defining ideal indications for each surgical procedure

Which patients should undergo...Biliopancreatic Diversion/DS - A. Pomp (New York, NY USA)Sleeve Gastectomy - M. Gagner (Montreal, QC, Canada)Gastric Bypass - P. Schauer (Cleveland, OH USA)Gastric Banding - J.B. Dixon (Melbourne, Australia)Novel GI Procedures: To re-route or not to re-route the bowel? - R.V. Cohen (São Paulo, Brazil)

Expert Panel CommentsH. Buchwald (Minneapolis, MN USA), P. Chowbey (New Delhi, India), A.L. De Paula (Goiânia, Brazil),J.W.M. Greve (Heerleen, Netherlands)


Workshop C: Defining and measuring success of surgical treatment of diabetes

Definition of success and appropriate clinical measures to assess outcomes of surgicaltreatmentJ.I. Mechanick (New York, NY USA)

Expert Panel CommentsH.J. Sugerman (Richmond, VA USA), J. Korner (New York, NY USA), R. DeFronzo (San Antonio, TX USA),S.R. Joshi (Mumbai, India)


4:50 pm - 5:25 pm

4:50 pm - 4:55 pm

4:55 pm - 5:10 pm

5:10 pm - 5:25 pm

5:25 pm - 6:20 pm

5:25 pm - 5:50 pm

5:50 pm - 6:05 pm

6:05 pm - 6:20 pm

6:20 pm - 6:50 pm

6:20 pm - 6:25 pm

6:25 pm - 6:40 pm

6:40 pm - 6:50 pm


CLINICAL TRACK 4:50 pm - 6:50 pm Sutton North/Beekman

Defining appropriate surgical candidates and good clinical practice for perioperative management andpost-operative follow-up

Chairs: H.E. Lebovitz (Brooklyn, NY USA) • P. Schauer (Cleveland, OH USA)


Scientific Program

Workshop A: Defining mechanisms of action of surgery and their implications for futurediabetes therapies and understanding of disease mechanisms

Mechanisms of action of metabolic surgery: what is clear and what is notLessons for future pharmacologic therapiesLessons about diabetes/obesity pathophysiologyL. Kaplan (Boston, MA USA)

Expert Panel CommentsG. Mingrone (Rome, Italy), G. Schwartz (Bronx, NY USA), B.B. Laferrere (New York, NY USA),R.N. Bergman (Los Angeles, CA USA)


Workshop B: Defining appropriate methods of innovation in bariatric and metabolicsurgery and novel interventional treatments for diabetes

Defining proper clinical and pre-clinical assessment of new surgical procedures and devicesC.W. Le Roux (London, UK)

Expert Panel CommentsB.M. Hofmann (Oslo, Norway), M.Galvao Neto (São Paulo, Brazil), S. Klein (St. Louis, MO USA), S. Del Prato(Pisa, Italy)


Workshop C: Defining priorities for clinical research

Diabetes surgery: the most compelling clinical issues that require priority testing byrandomized clinical trialsD.E. Cummings (Seattle, WA USA)

Expert Panel CommentsA.B. Goldfine (Boston, MA USA), M. Staten (Bethesda, MD USA), S.H. Kahn (Seattle, WA USA),X. Pi-Sunyer (New York, NY USA), D. Lautz (Boston, MA USA)


4:50 pm - 5:35 pm

4:50 pm - 5:00 pm

5:00 pm - 5:20 pm

5:20 pm - 5:35 pm

5:35 pm - 6:10 pm

5:35 pm - 5:40 pm

5:40 pm - 5:55 pm

5:55 pm - 6:10 pm

6:10 pm - 6:50 pm

6:10 pm - 6:15 pm

6:15 pm - 6:35 pm

6:35 pm - 6:50 pm


RESEARCH TRACK 4:50 pm - 6:50 pm Sutton Center

Defining priorities for clinical trials and investigations on mechanisms of action of surgeryChairs: L. Kaplan (Boston, MA USA) • D.E. Cummings (Seattle, WA USA)




Scientific Program

TUESDAY, MARCH 29, 2011 (continued)


Workshop A: Creating a pathway to reconcile professional guidelinesP. Zimmet (Melbourne, Australia)

Panel Discussion/Round Table with official representatives of the following organizations:NHLBI Obesity Guidelines (X. Pi-Sunyer, New York, NY USA), ADA (M.S. Kirkman, Alexandria, VA USA),AACE (J.I. Mechanick, New York, NY USA), ASMBS (B. Wolfe, Portland, OR USA), TOS (C.M. Apovian,Boston, MA USA), SBCBM (R.V. Cohen, São Paulo, Brazil), SICOB (N. Basso, Rome, Italy), IFSO(M. Lakdawala, Mumbai, India)

Interactive Opinion Polls

Workshop B: Payer perspectives: creating a pathway for policymakers and payers toreconcile approachesD. Flum (Seattle, WA USA)

Panel Discussion/Round TableF. Lefevre (Chicago, IL USA), S.D. Sullivan (Seattle, WA USA), J. Funder (Clayton, Australia), L. Ji (Beijing,China), C. Keating (Buswood, Australia), T. Van Der Merwe (Pretoria, South Africa), P. Hill (Doha, Qatar),J.J. Moore (Blue Bell, PA USA)

Interactive Opinion Polls

4:50 pm - 5:50 pm

5:00 pm - 5:40 pm

5:40 pm - 5:50 pm

5:50 pm - 6:50 pm

6:00 pm - 6:40 pm

6:40 pm - 6:50 pm

POLICY TRACK 4:50 pm - 6:50 pm Sutton South/Regent

Proposing practical solutions to improve access to surgery when indicatedChairs: P. Zimmet (Melbourne, Australia) • D. Flum (Seattle, WA USA)




Scientific Program

RESEARCH TRACK SESSION IV 9:00 am - 10:40 am Grand Ballroom

9:00 am - 9:20 am

9:20 am - 9:40 am

9:40 am - 10:00 am

10:00 am - 10:20 am

10:20 am - 10:40 am

10:40 am - 11:00 am

Conventional paradigm of the pathophysiology of obesityR.L. Leibel (New York, NY USA)

Conventional paradigm of the pathophysiology of diabetesR.N. Bergman (Los Angeles, CA USA)

The physiologic role of the gut in energy and glucose homeostasisJ.J. Holst (Copenhagen, Denmark)

The role of intestinal microbiota in insulin resistance, obesity/diabetesR.E. Ley (Ithaca, NY USA)

Impaired GI physiology in individuals with diabetes/obesityD.E. Cummings (Seattle, WA USA)


WEDNESDAY, MARCH 30, 2011

The role of the gut in the physiology and pathophysiology of obesity and diabetes

Chairs: T.E. McGraw (New York, NY USA) • D. Accili (New York, NY USA)

KEYNOTE LECTURE 8:00 am - 9:00 am Grand Ballroom

Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis

M.S. Brown (Dallas, TX USA)

J.L. Goldstein (Dallas, TX USA)

The Nobel Prize in Physiology or Medicine 1985 was awarded jointly to Michael S. Brown andJoseph L. Goldstein “for their discoveries concerning the regulation of cholesterol metabolism”.

8:00 am - 9:00 am

PANEL DISCUSSION 11:00 am - 12:00 pm Grand Ballroom

11:00 am - 11:05 am

11:05 pm - 12:00 pm

IntroductionF. Rubino (New York, NY USA)

Panel DiscussionM.S. Brown (Dallas, TX USA), J.L. Goldstein (Dallas, TX USA), G. Shulman (New Haven, CT USA),S. Klein (St. Louis, MO USA), R. DeFronzo (San Antonio, TX USA), S.E. Kahn (Seattle, WA USA),J. Roth (Manhasset, NY USA), L.M. Kaplan (Boston, MA USA)

The GI tract: could it be the missing link between obesity and diabetes?


Scientific Program

CONTINENTAL BREAKFAST (Grand Ballroom Foyer)7:00 am - 8:00 am


WEDNESDAY, MARCH 30, 2011 (continued)

EXECUTIVE SUMMARIES/TAKE HOME MESSAGE 12:00 pm - 1:15 pm Grand Ballroom

12:00 pm - 12:12 pm

12:12 pm - 12:24 pm

12:24 pm - 12:36 pm

12:36 pm - 12:48 pm

12:48 pm - 1:00 pm

1:00 pm - 1:15 pm

1:15 pm - 1:20 pm

Clinical PracticeH.E. Lebovitz (Brooklyn, NY USA)

Priorities for Clinical ResearchD.E. Cummings (Seattle, WA USA)

Reconciling GuidelinesP. Zimmet (Melbourne, Australia)

Public Health PoliciesD. Flum (Seattle, WA USA)

The evolving paradigm of diabetes pathogenesisJ. Roth (Manhasset, NY USA)

INTERACTIVE OPINION POLLS

CLOSING REMARKS

Presentation of Executive Summaries and Conclusions

Chairs: M. Sue Kirkman (Alexandria, VA USA) • W. Pories (Greenville, NC USA)


Scientific Program



Faculty Index


AAccili, Domenico . . . . . . . . . . . . . . . . . . . . . . . . . . .Adams, Ted D. . . . . . . . . . . . . . . . . . . . . . . . . . . . .Alberti, K. George . . . . . . . . . . . . . . . . . . . . . . . .Amiel, Stephanie A. . . . . . . . . . . . . . . . . . . . . . . . . .Apovian, Caroline M. . . . . . . . . . . . . . . . . . . . . . .Aronne, Louis . . . . . . . . . . . . . . . . . . . . . . . . . .

BBasso, Nicola . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Bergman, Richard N. . . . . . . . . . . . . . . . . . .Bloomgarden Zachary T. . . . . . . . . . . . . . . . . . . . . . .Brethauer, Stacy A. . . . . . . . . . . . . . . . . . . . . . . . . .Brown, Michael S. . . . . . . . . . . . . . . . . . . . . . . . . . .Buchwald, Henry . . . . . . . . . . . . . . . . . . . . . .

CChowbey, Pradeep . . . . . . . . . . . . . . . . . . . . . . .Cohen, Ricardo V. . . . . . . . . . . . . . . . . . . .Cummings, David E. . . . . . . . . . . . . . . . . .

DDarsow, Tamara . . . . . . . . . . . . . . . . . . . . . . . . . . .Darzi, Ara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .DeFronzo, Ralph . . . . . . . . . . . . . . . . .De Paula, Aureo . . . . . . . . . . . . . . . . . . . . . . . . .Del Prato, Stefano . . . . . . . . . . . . . . . . . . . . .Dixon, John . . . . . . . . . . . . . . . . . . . . . . . . .

EEckel Robert H. . . . . . . . . . . . . . . . . . . . . . . . . .

FFerrannini, Ele . . . . . . . . . . . . . . . . . . . . . . . . . .Flum, David R. . . . . . . . . . . . . . . . . . . . . . . .Funder, John . . . . . . . . . . . . . . . . . . . . . . . .

GGagner, Michel . . . . . . . . . . . . . . . . . . . . . . . . . .Galvao Neto, Manoel . . . . . . . . . . . . . . . . . . . . . .Goldfine Allison B. . . . . . . . . . . . . . . . . . . . . . .Goldstein, Joseph L. . . . . . . . . . . . . . . . . . . . . . . . . .Gotto, Antonio M. . . . . . . . . . . . . . . . . . . . . . . . .Greve, Jan Willem M. . . . . . . . . . . . . . . . . . . . . . .

HHill, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hofmann, Bjørn M. . . . . . . . . . . . . . . . . . . . . . . .Holst, Jens Juul . . . . . . . . . . . . . . . . . . . . . . . . .

JJi, Linong . . . . . . . . . . . . . . . . . . . . . . . . . . .Joshi, Shashank R. . . . . . . . . . . . . . . . . . . . . .

KKahn, Steven H. . . . . . . . . . . . . . . . . . . . . . .Kaplan, Lee M. . . . . . . . . . . . . . . . . . . . . .Keating, Catherine . . . . . . . . . . . . . . . . . . . . . . . .Kirkman, M. Sue . . . . . . . . . . . . . . . . . . . . . . . . .Klein Samuel . . . . . . . . . . . . . . . . . . . . . . . . .Korner, Judith . . . . . . . . . . . . . . . . . . . . . .

35

LLaferrere, Blandine B. . . . . . . . . . . . . . . . . . . . . .Lakdawala, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . .Lautz, David B. . . . . . . . . . . . . . . . . . . . . . . . . .Lebovitz, Harold E. . . . . . . . . . . . . . . .Lefevre, Frank . . . . . . . . . . . . . . . . . . . . . . . . . .Leibel, Rudolph L. . . . . . . . . . . . . . . . . . . . . . . . . . .LeRoux, Carel W. . . . . . . . . . . . . . . . . . . . . . . . .Ley Ruth, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Li, Rui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

MMcGraw, Timothy E. . . . . . . . . . . . . . . . . . . . . . . . . .Mechanick, Jeffrey I. . . . . . . . . . . . . . . . . .Mingrone, Geltrude . . . . . . . . . . . . . . . . . . . . . . .Moore, J.J. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PPi-Sunyer, Xavier . . . . . . . . . . . . . . . . . . . . . .Pomp, Alfons . . . . . . . . . . . . . . . . . . . . . . . . . . .Pories, Walter J. . . . . . . . . . . . . . . . . .

RRoth, Jesse . . . . . . . . . . . . . . . . . . . . . . . . .Rubino, Francesco . . . . . . . . . . . . . . . . . . . . .

SSaoud, Moh'd. Fathy . . . . . . . . . . . . . . . . . . . . . . . .Schauer, Phillip . . . . . . . . . . . . . . . . . . . . . . .Schwartz, Gary J. . . . . . . . . . . . . . . . . . . . . . . . .Seeley, Randy J. . . . . . . . . . . . . . . . . . . . . . . . . . . .Shulman, Gerald . . . . . . . . . . . . . . . . . . . . . . . . . . .Sjöström, Lars V. . . . . . . . . . . . . . . . . . . . . . . . .Staten, Myrlene . . . . . . . . . . . . . . . . . . . . . . . . .Sugerman, Harvery J. . . . . . . . . . . . . . . . . . . . . .Sullivan, Sean D. . . . . . . . . . . . . . . . . . . . . . . . .

VVan Der Merwe, Tess . . . . . . . . . . . . . . . . . . . . . .

WWolfe, Bruce M. . . . . . . . . . . . . . . . . . . . . . . . . .Wysham, Carol H. . . . . . . . . . . . . . . . . . . . . . . . .

YYoung, James . . . . . . . . . . . . . . . . . . . . . . . . . .

ZZimmet, Paul . . . . . . . . . . . . . . . . . . . . . .Zirie, Mahmoud Ali . . . . . . . . . . . . . . . . . . . . . . . . . .

3327

26, 2726

27, 3227, 30

3227, 28, 31, 33

262833

26, 28, 30

29, 3027, 28, 30, 3228, 31, 33, 34

2929

27, 28, 29, 30, 3328, 30

26, 27, 3126, 27, 30

26, 27

27, 2829, 32, 3428, 29, 32

27, 3028, 31

26, 29, 3133

26, 2728, 30

3229, 3128, 33

27, 29, 3227, 28, 30

27, 28, 31, 3326, 28, 31, 33

29, 3232, 34

28, 31, 3327, 28, 29, 30

28, 3132

29, 3126, 27, 28, 30, 34

29, 3233

28, 313329

3326, 27, 30, 32

28, 3129, 32

26, 31, 3226, 30

26, 27, 28, 30, 34

29, 33, 3426, 29, 33

2926, 29, 30

28, 312833

26, 2729, 3127, 3029, 32

29, 32

26, 3226, 27

27, 30

26, 29, 32, 3429

Pre-Purchase your Congress DVD today!

Share the World Congresswith your Staff and Colleagues!

The information presented at the 2nd World Congress onInterventional Therapies for Type 2 Diabetes is an invaluableresource. The Congress DVD is the perfect way to shareall the valuable information you’ve heard here with yourcolleagues and staff.

The Congress DVD will include the full sessionrecordings and slides from all presentations duringthe Congress, including the discussions in eachof the three breakout tracks.

Purchase the DVD at the Congress Registration Deskor after the Congress at www.wcidt.org

Cost: $165 (plus shipping)DVD orders will be mailed in summer 2011.

EXHIBITOR DIRECTORY


American Diabetes FoundationBooth 207

Linda [email protected]

The American Diabetes Association is the leading non-profitorganization focused on providing resources to health careprofessionals and people with diabetes to improve care andpatient outcomes. The association has a worldwide professionalmembership of over 15,000 and over 425,000 lay members.Join the new grassroots movement to “Stop Diabetes.”

AllerganBooth 104

Pat [email protected]

Allergan has joined the effort to fight the growing obesityepidemic with the LAP-BAND® Adjustable Gastric BandingSystem, the first minimally invasive surgical approach approvedin the United States by the FDA, to help patients achievesustained weight loss, realize their goals for healthy living, andreduce obesity-related risks.

CovidienBooth 100

Gaurav [email protected]

Gina [email protected]

Covidien is a leading global healthcare products company thatcreates innovative medical solutions for better patient outcomesand delivers value through clinical leadership and excellence.Covidien manufactures a diverse range of industry-leadingproducts in five segments including Surgical and Energy-basedDevices. Please visit www.covidien.com to learn more.

GI DynamicsBooth 106

Wade [email protected]

GI Dynamics is focused on developing effective, non-surgicalapproaches for treating type 2 diabetes and obesity. Thecompany's patented EndoBarrier™ technology has the potentialto deliver medical innovations for people combating diabetesand weight problems or diabetes risk factors. Data from clinicaltrials demonstrate that the EndoBarrier may provide rapidimprovement in glycemic control and significant weight loss bymodifying metabolic pathways.

Gore Medical ProductsBooth 202

Pamela [email protected]

Gore Medical Products Division has provided creativetherapeutic solutions to complex medical problems for threedecades. During that time, more than 35 million InnovativeGore Medical Devices have been implanted, saving andimproving the quality of lives worldwide. The extensive GoreMedical family of products includes vascular grafts, endovascularand interventional devices, surgical materials for hernia repair,soft tissue reconstruction, staple line reinforcement, and suturesfor use in vascular, cardiac and general surgery.

Ethicon Endo-SurgeryBooth 102

Annie [email protected]

Ethicon Endo-Surgery, a Johnson & Johnson company,develops and markets advanced medical devices for minimallyinvasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatmentof conditions in general and bariatric surgery, as well asgastrointestinal health, gynecology and surgical oncology.More information can be found at www.ethiconendo.com.


Karl Storz Endoscopy-America Inc.Booth 204

Julia [email protected]

KARL STORZ Endoscopy-America, a leader for 65 years inendoscopy technologies, has earned a reputation for morethan its high-quality products. The company is also wellregarded for its commitment to advancing medical technologyand research programs. Among these is dedication to theresearch of Interventional Therapies for Type II Diabetes.

Qatar Foundation andHamad Medical CorporationBooth 203

Ramez [email protected]

Qatar Foundation for Education, Science and CommunityDevelopment (QF) is supporting Qatar on its journey fromcarbon economy to knowledge economy by unlocking humanpotential. This will not just benefit Qatar. It will benefit the world.QF is a private, non-profit organization founded in 1995 by HisHighness Sheikh Hamad Bin Khalifa Al-Thani, Amir of Qatar.Its Chairperson and main driving force is Her Highness SheikhaMoza Bint Nasser.

QF carries out its mission through three strategic pillars:education, science and research, and community development.QF’s education pillar brings world-class universities to Qatar tohelp create an education sector in which young people candevelop the attitudes and skills required for a knowledgeeconomy. Meanwhile, its science and research pillar buildsQatar's innovation and technology capacity by developingand commercializing solutions through key sciences. Finally,its community development pillar helps foster a progressivesociety while also enhancing cultural life, protecting Qatar’sheritage and addressing immediate social needs in thecommunity.

For a complete list of QF’s initiatives and projects, visithttp://www.qf.org.qa

206 204 202

207 205 203

106 104 102

200

201

100

ENTRANCE

WIFIHOTSPOTAREA

Rhinelander Gallery - Exhibits and Posters


39

Poster Display and Viewing:Monday, March 28: 7:00 am - 6:45 pmTuesday, March 29: 6:30 am - 3:00 pm

Poster Sessions:One of the authors is required to attend his or her poster as follows.

The formal poster session will be on Monday March 28 from 5:45 pm-6:45 pm.The Presenting Author is highlighted in bold

Please refer to the Abstract Book for the complete listing of Poster Sessions and Abstracts

An Author Index is included immediately following the Abstracts Listing.

*Special Note: Posters marked with YIA are competing for the Young Investigator Award.

Please refer to the Abstract Book for

POSTER SESSIONSRhinelander Gallery



40 2nd World Congress on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org


Diabetes: A Global EpidemicDiabetes currently affects 285 million people worldwideand is expected to affect 438 million by 2030.

In 2010, the five countries with the largest numbers ofpeople with diabetes were India (50.8 million), China(43.2 million), the United States (26.8 million), Russia(9.6 million), and Brazil (7.6 million).

In 2010, the five countries with the highest diabetesprevalence in the adult population were Nauru (30.9%),United Arab Emirates (18.7%), Saudi Arabia (16.8%),Mauritius (16.2%), and Bahrain (15.4%).

By 2030, the largest increases in diabetes prevalence willtake place in developing countries.

Each year a further 7.7 million people develop diabetes.

Each year 4 million deaths are attributable to diabetes.An even greater number die from cardiovascular diseasemade worse by diabetes-related lipid disorders andhypertension.

Every 10 seconds a person dies from diabetes-relatedcauses.

Every 10 seconds two people develop diabetes.

Diabetes is the fourth leading cause of global death bydisease.

At least 50% of all people with diabetes are unaware oftheir condition. In some countries this figure may reach80%.

At least 60% of new cases of type 2 diabetes ispreventable by adopting a healthy diet and increasingphysical activity.

Diabetes is the largest cause of kidney failure in developedcountries and is responsible for huge dialysis costs.

Type 2 diabetes has become the most frequentcondition in people with kidney failure in countries of theWestern world. The reported incidence variesbetween 30% and 40% in countries such as Germanyand the USA.

10% to 20% of people with diabetes die of renal failure.

It is estimated that more than 2.5 million peopleworldwide are affected by diabetic retinopathy.

Diabetic retinopathy is the leading cause of visionloss in adults of working age (20 to 65 years) inindustrialized countries.

On average, people with type 2 diabetes will die 5-10years before people without diabetes, mostly due tocardiovascular disease.

Cardiovascular disease is the major cause of death indiabetes, accounting for some 50% of all diabetesfatalities, and much disability.

People with type 2 diabetes are over twice as likely tohave a heart attack or stroke as people who do not havediabetes. Indeed, people with type 2 diabetes are as likelyto suffer a heart attack as people without diabetes whohave already had a heart attack.

Sources:Diabetes Atlas, fourth edition,International Diabetes Federation, 2009.Diabetes Fact Sheets:Time to Act, International Diabetes Federation, 2004.World Health Organisation Diabetes Unit - www.who.int/diabetes.

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

Diabetes currently affects 285 million people worldwide,according to the International Diabetes Federation (IDF).


Roux-en-Y Gastric Bypass (RYGB)

After its first report by Edward Mason in 1967, thetechnique of gastric bypass has undergone severalmodifications. The current technique involves the use ofa surgical stapler to create a small and vertically orientedgastric pouch usually less than 30 cc in size. The upperpouch, which is completely divided from the gastricremnant is anastomosed to the jejunum (between 30 and75 cm from the ligament of Treitz). Bowel continuity isrestored by an entero-entero anastomosis between theexcluded biliary limb and the alimentary limb usually75-to 100 cm distal to the gastro-jejunostomy. AfterRYGB, ingested food bypasses approximately 95% ofthe stomach, the entire duodenum and a portion of thejejunum, but bile and nutrients mix in the distal jejunumand can be absorbed through the remaining portion ofthe small bowel (jejunum-ileum).

Conventional Bariatric/Metabolic Procedures



Laparoscopic Adjustable Gastric Banding (LAGB)

The LAGB is a restrictive procedure that involves encirclingthe upper part of the stomach with a band-like, saline-filledtube just distal to the gastroesophageal junction. Theamount of restriction may be adjusted by injecting orwithdrawing saline solution from the hollow core of theband through a subcutaneous port.

Sleeve Gastrectomy (SG)

Sleeve gastrectomy is a component of BPD-DS; an opera-tion that can be performed in two stages (sleeve gastrec-tomy first, followed by the intestinal rearrangement monthslater) to reduce operative time and minimize surgical risk insuper-obese patients (BMI>60). The dramatic weight lossconsequent to the first stage of the BPD-DS hasencouraged the use of SG as a stand-alone procedure.In addition to reducing the capacity of the stomach, SGeliminates the ghrelin-rich gastric fundus and can causechanges in intra-gastric pressure and gastric motility, allof which might play a role in the mechanism of action ofthe operation. Sleeve gastrectomy has been also shown tosubstantially improve diabetes in severely obese patientsas well as in experimental rodent models of diabetes. Thelong-term (>5 years) clinical efficacy of the procedure is stillunder investigation.


Biliopancreatic Diversion (BPD) and BPD-DS

The operation involves a gastric resection (usually leavingbehind a 200-500 ml sized stomach) + a long intestinalbypass. The gastric resection can be horizontal as in theScopinaro procedure (Fig 1A) or vertical - “sleevegastrectomy” in its variant named “BPD-DuodenalSwitch”- Fig 1B). The remnant stomach is anastomosedto the distal 250 cm of small intestine (called alimentarylimb). The excluded small intestine (including theduodenum, the jejunum and part of the proximal ileum)carries the bile and pancreatic secretions (biliary limb) andis connected to the alimentary channel just 50-100 cmproximal to the ileocecal valve. The short segment of smallbowel where bile and nutrients mix is called “commonlimb” and is the only site where fat and starches areabsorbed, whereas the alimentary limb (usually 200-250cm in length) allows only partial absorption of nutrients.


Figure 1A

Figure 1B


Duodenal-Jejunal Bypass (DJB)

Originally described by Rubino as an experimentalprocedure to investigate mechanisms of action of gastricbypass surgery, the operation consists of a stomach-preserving bypass of a short segment of proximal smallintestine, equivalent to the amount of intestine bypassedin a standard gastric bypass (RYGB). A variant of thisprocedure includes the association of proximal intestinalbypass with sleeve resection of the stomach (DJB-SG-Fig 2B) to reduce potential for marginal ulcerations andpotentially increase clinical efficacy. These procedureshave been used to treat diabetes in low BMI patients(R. Cohen and others). Long-term efficacy data are notyet available and these procedures should be consideredinvestigational in humans.

Figure 2A

Figure 2B

Investigational Gastrointestinal Procedures


Ileal Interposition (IT)

The concept of ileal-interposition was first described byKoopmans and Sclafani in rodents experiments as aweight loss procedure. A small segment of ileum with itsvascular and nervous supplies intact, is surgically interposedinto the proximal small intestine, accelerating its exposureto ingested nutrients. IT can be performed alone or inassociation with sleeve gastrectomy and duodenal exclusion.The procedure requires a minimum of 3 anastomosis(vs the 2 of gastric bypass operations) and is technicallycomplex, especially when associated with sleevegastrectomy or duodenal exclusion. Early human studiessuggest that these procedures can improve diabetes innon-obese subjects; however, long-term metabolicsequalae are unknown, and long-term safety is still to beevaluated. The procedure should be consideredexperimental in humans.

Investigational Gastrointestinal Procedures


Disclosures


Consultant: Amylin, Orexigen, Allergan, Pfizer, Johnson &Johnson, Abott, Merck, GI DynamicsGrant/Research: Atkins Foundation, MetaProteomics, Amylin,Orexigen

Contracted Research: Amylin Pharmaceuticals, Inc.,F. Hoffmann-La Roche Ltd., Novo Nordisk, OrexigenTherapeutics, Inc.Consultant/Advisory Boards: Abbott Laboratories, AmylinPharmaceuticals, Inc., GI Dynamics, Inc., Roche Laboratories,Inc., Johnson & Johnson, NeuroSearch, Inc., Novo Nordisk,Orexigen Therapeutics, Inc., VIVUS, Inc., GlaxoSmithKlineConsumer Healthcare, LPOwnership Interest: Cardiometabolic Support Network, LLC

Consultant: TethysGrant/Research Support (Principal): Amylin

Consultant: BMS/AZ, Merck, Novo NordiskSpeaker’s Bureau: Merck, Novo Nordisk, GlaxoSmithKlien,BMS BIStock Shareholder (self managed): Bard, CVS, Roche, Novartis,St. Jude

Consultant: Ethicon EndoSpeaker’s Bureau: Ethicon Endo, CovidienGrant/Research Support (Principal): Bard/Davol, Ethicon Endo

Consultant: Ethicon Endo-Surgery, Fulfillium, MetacureGrant/Reserach Support (Principal): Meacure, EthiconEndo-Surgery, WE GoreStock Shareholder (self managed): Metacure

Grant/Research (Principal): Johnson & Johnson, EthiconEndosurgery

Stock Shareholder (self managed): Amylin

Consultant: Covidien

Consultant: Takeda, Amylin, ISIS, Boehringer IngelheimSpeaker’s Bureau: Novo NordiskGrant/Reserach Support (Principle): Takeda, Amylin

Speaker’s Bureau: GlaxoSmithKline, Sanofi-AventisGrant/Research Support (Principle): Merck & Co., Sanofi-Aventis,Novo NordiskAdvisory Panels: Novartis Pharmaceuticals, Merck & Co.,Roche Pharmaceuticals, Roche Diagnostics Corporation, PfizerInc., Eli Lilly & Co., Amylin Pharmaceuticals, Inc., MannkindCorporation; Boehringer Ingelheim, Bristol-Meyers Squibb,Novo Nordisk

Dixon, John B.

Funder, John

Gagner, Michel

Galvao Neto, Manoel

Greve, Jan Willem M.

Kahn, Steven H.

Kaplan, Lee

Keating, Catherine

Klein, Samuel

Korner, Judith

Lautz, David

Lebovitz, Harold E.

Apovian, Caroline M.

Aronne, Louis J.

Bergman, Richard N.

Bloomgarden, Zachary T.

Brethauer, Stacy A.

Buchwald, Henry

Cummings, David E.

Darsow, Tamara

Darzi, Ara

DeFronzo, Ralph

Del Prato, Stefano

Consultant: Allergan Inc., Metagenics (Bariatric Advantage),Scientific IntakeSpeaker’s Bureau: Metagencis (Bariatirc Advantage), Eli Lilly,Nestle Australia, Optifast Medical Advisory BoardGrant/Research (Principal): Allergan Inc., Nestle Australia, Opti-fast Medical Advisory Board, ResMed, Scientific IntakeCourse Director: Florida HospitalCourse Co-Director: MISS

Consultant: Pfizer, Merck, CBio, Allergan, Novo NorDisk

Speaker’s Bureau: Ethicon, Olympus, CineMed, CovidenGrant/Research Support (Principal): GORE

Consultant: Ethicon Endo Surgery, GI Dynamics

Consultant: GI DynamicsGrant/Research Support (Principal): GI Dynamics

Consultant: Boenringer Ingelheim, Eli Lilly, GlaxoSmithKlien,Intarcia Therapeutics, Merck, Novo NordiskGrant/Research: Daiichi Sankyo

Consultant: GI DynamicsGrant/Research (Principal): GI Dynamics

Grant/Research Support (Principal): Allergan Health

Consultant: Amylin, Dannon/Yakult, Ethicon Endosurgery,Merck, Orexigen, Takeda Pharmaceuticals, VivusPharmaceuticalsSpeaker’s Bureau: MerckGrant/Research Support (Principal): National Institute of Health(NIH), Barnes-Jewish Hospital Foundation, DSM NutritionalProducts, Endo-Ethicon Surgery, PfizerStockholder: Aspirations Medical TechnologiesEndowments: Atkins Foundation Charitable Trust, KiloFoundation

Grant/Research Support (Principal): CovidienScientific Advisory Board: Nutrisystem

Grant/Research (Principal): Covidien

Consultant: Amylin Corporation, Astra-Zeneca, Biocon Pharma,Enzymotec, Glaxo Smith Kline (International), MetaCure,Sanofi-AventisSpeaker’s Bureau: Glaxo Smith Kline (International)Stockholder: MerckAdvisory Board: Amylin Corporation, ATTCC, Biocon Pharma,Indigene, Intra Pharmaceuticals, Merck, MetaCure, Poxel Pharma

Faculty Disclosures


48

Disclosures

Consultant: Amylin, McNeil Nutritionals, Novo Nordiak, VivusInc., Weight Watchers, Orezigen

Consultant: Johnson & JohnsonGrant/Research (Principal): Johnson & Johnson, GlaxoSmithKline

Consultant: NGM BiotechGrant/Research Support (Principal): Covidien, Roche

Consultant: GoreGrant/Research (Principal): Baxter, Covidien, AllerganBoard of Directors: Remedy MD, Surgical Excellence LLCScientific Advisory Board: Ethicon Endosurgery, StrykerEndoscopy, Bard-Davol, Barosense, Surgiquest,Cardinal/Snowden Pencer

Pi-Sunyer, Xavier

Pories, Walter J.

Rubino, Francesco

Schauer, Phillip

Faculty Disclosures


Consultant: Ethicon EndoSpeaker’s Bureau: Novo NordiskGrant/Research Support (Principal): Ethicon Endo, NovoNordisk

Consultant: AZ, Johnson & Johnson, SeveralGrant/Research Support (Principle): Johnson & Johnson,Roche, Sanofi

Consultant: Amylin PharmaceuticalsSpeaker’s Bureau: Sanofi Aventis, Amylin Pharma

Seeley, Randy J.

Sjöström, Lars V.

Wysham, Carol H.


Faculty With No Conflicts of Interest

Accili, DomenicoAdams, Ted D.Alberti, Sir K. GeorgeAmiel, Stephanie A.Basso, NicolaBrown, Michael S.Chowbey, PradeepCohen, Ricardo V.De Paula, Aureo LudovicoEckel, Robert H.Ferrannini, EleFlum, David R.Goldfine, Allison B.Goldstein, Joseph L.Gotto, Jr., Antonio M.Hill, PeterHofmann, BjornHolst, Jens Juul HolstJi, LinongJoshi, Shashank R.Kirkman, SueLaferrere, Blandine B.Lakdawala, Muffazal AbdulkaderLe Roux, Carel W.Lefevre, FrankLeibel, Rudolph L.Ley, RuthLi, RuiMcGraw, Timothy E.Mechanick, Jeffrey I.Mingrone, GeltrudeMoore, John J.Pomp, AlfonsRoth, JesseSaoud, Mohammed FathySchwartz, GaryShulman, GeraldStaten, MyrleneSugerman, Harvey J.Sullivan, Sean D.Van Der Merwe, TessWolfe, BruceYoung, JamesZimmet, PaulZirie, Mahmoud Ali


Visionary Level Supporter

Platinum Level

Gold Level

Silver Level

We would also like to thank

Bronze Level

Corporate Sponsors

50

G.R.I.N. FOUNDATION


Giovanni Lorenzini Medical Foundation6535 Fannin, MS A-601

Suite A754Houston, TX 77030

Tel: +1 713 797 0401 • Fax: +1 713 796 8853

www.wcidt.org

2ndWorldCongresson InterventionalTherapiesforType2Diabetes › download... · HostedBy March 28-30,...

Documents

Transcript of 2ndWorldCongresson InterventionalTherapiesforType2Diabetes › download... · HostedBy March 28-30,...